The video perspective from the ARVO meeting discusses how central retinal thickness in patients with diabetic macular edema can impact their treatment journey. Data from the PHOTON study showed that patients with more swollen retinas and higher levels of VEGF required the additional VEGF suppression offered by 8 mg aflibercept to maintain anatomy and improve durability. The study emphasized the importance of baseline central retinal thickness in determining the severity of diabetic macular edema and the need for personalized treatment approaches based on individual patient needs. Financial disclosures for the presenter were also provided.
Source link
Patients with severe DME benefit from high-dose aflibercept
